Male pattern baldness may soon be cured thanks to new drug

A huge worry amongst a lot of men

A pharmaceutical company on Wednesday announced the results of its two phase III trials testing out the topical drug clascoterone for male androgenetic alopecia, and compared to placebo, people on clascoterone gained back significantly more hair.

In fact, one trial showed a roughly 500% improvement in hair restoration.

A potential FDA approval could happen next year thanks to these results, and clascoterone could be the first truly novel treatment for pattern baldness seen in decades.

There already are effective medications for male pattern baldness, such as minoxidil and finasteride, not to mention the hair transplants.

However, not only are some of them costly but they also come with drawbacks, and they might simply not work for you if they did for somebody else.

But what causes male pattern baldness?

Mainly by having genes that will make your hair’s follicles overly sensitive to androgens, that is the male-related sex hormones.

Cosmo Pharmaceuticals now hopes that clascoterone can become the first of a new class of drugs for hair loss.

This drug is known as an androgen receptor inhibitor, so it targets the hormones that help cause the loss of your hair follicles.

The risk of potential side effects is minimised because clascoterone isn’t systemically absorbed by the body and it appears to be safe and tolerable, according to the Dublin-based company.

It is estimated that up to 50% of men will experience some pattern baldness by age 50.